Abstract
The synthesis and biological evaluation of 5′-guanidino furanosyl nucleosides comprising 6-chloropurine and uracil moieties and a 3-O-benzyl xylofuranosyl unit is presented. Their access was based on the N-glycosylation of a 5-azido 3-O-benzyl xylofuranosyl acetate donor with the silylated nucleobase and a subsequent one-pot sequential two-step protocol involving Staudinger reduction of the thus obtained 5-azido uracil and N7/N9-linked purine nucleosides followed by guanidinylation with N,N’-bis(tert-butoxycarbonyl)-N’’-triflylguanidine.
Bioactivity screening revealed the significant activities exhibited among the synthesized compounds, namely abilities to inhibit butyrylcholinesterase (BChE), a therapeutic target for the symptomatic treatment of latter stages of Alzheimer’s disease, cytotoxic activities against cancer cells, and/or neuroprotective effects.
5′-Guanidino 6-chloropurine nucleosides were shown to act as mixed-type and selective submicromolar or micromolar BChE inhibitors, from which the N9 nucleoside was the most prominent compound with inhibition constants Ki / Ki' of 0.89 μM / 2.96 μM, besides showing low cytotoxicity to FL83B hepatocytes and no significant cytotoxicity to human neuroblastoma cells (SH-SY5Y). Moreover, the N9-linked nucleoside exhibited selective cytotoxic activity to prostate cancer cells (DU-145, IC50 = 27.63 μM), while its N7 regioisomer was active against all cancer cells tested [DU-145, IC50 = 24.48 μM; colorectal adenocarcinoma (HCT-15, IC50 = 64.07 μM); and breast adenocarcinoma (MCF-7, IC50 = 43.67 μM)]. In turn, the 5'-guanidino uracil nucleoside displayed selective cytotoxicity to HCT-15 cells (IC50 = 76.02 μM) and showed also neuroprotective potential in a Parkinson’s disease SH-SY5Y cells’ damage model. The active molecules exhibited IC50 values to the affected cancer cells close or lower than those of standard drugs, and comparable or not significant neuro- and hepatotoxicity.



![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://www.cambridge.org/engage/assets/public/coe/logo/orcid.png)